Daniel D. Hodgkiss

Daniel D. Hodgkiss

Auto-generated profile, based on publicly available information

Daniel D. Hodgkiss

School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2023 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
DHDaniel D. Hodgkiss
Daniel D. Hodgkiss
GBGurjeet S. Bhangu
Gurjeet S. Bhangu
CLCarole Lunny
Carole Lunny
CJCatherine J. Jutzeler
Catherine J. Jutzeler
SCShin-Yi Chiou
Shin-Yi Chiou
TNTom E. Nightingale
Tom E. Nightingale
Background: A low level of cardiorespiratory fitness [CRF; defined as peak oxygen uptake ( V˙ O2peak) or peak power output (PPO)] is a widely reported consequence of spinal cord injury (SCI) and a major risk factor associated with chronic disease. However, CRF can be modified by exercise. This systematic review with meta-analysis and meta-regression aimed to assess whether certain SCI characteristics and/or specific exercise considerations are moderators of changes in CRF. Methods and findings: Databases (MEDLINE, EMBASE, CENTRAL, and Web of Science) were searched from inception to March 2023. A primary meta-analysis was conducted including randomised controlled trials (RCTs; exercise interventions lasting >2 weeks relative to control groups). A secondary meta-analysis pooled independent exercise interventions >2 weeks from longitudinal pre-post and RCT studies to explore whether subgroup differences in injury characteristics and/or exercise intervention parameters explained CRF changes. Further analyses included cohort, cross-sectional, and observational study designs. Outcome measures of interest were absolute (A V˙ O2peak) or relative V˙ O2peak (R V˙ O2peak), and/or PPO. Bias/quality was assessed via The Cochrane Risk of Bias 2 and the National Institute of Health Quality Assessment Tools. Certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Random effects models were used in all meta-analyses and meta-regressions. Of 21,020 identified records, 120 studies comprising 29 RCTs, 67 pre-post studies, 11 cohort, 7 cross-sectional, and 6 observational studies were included. The primary meta-analysis revealed significant improvements in A V˙ O2peak [0.16 (0.07, 0.25) L/min], R V˙ O2peak [2.9 (1.8, 3.9) mL/kg/min], and PPO [9 (5, 14) W] with exercise, relative to controls (p < 0.001). Ninety-six studies (117 independent exercise interventions comprising 1,331 adults with SCI) were included in the secondary, pooled meta-analysis which demonstrated significant increases in A V˙ O2peak [0.22 (0.17, 0.26) L/min], R V˙ O2peak [2.8 (2.2, 3.3) mL/kg/min], and PPO [11 (9, 13) W] (p < 0.001) following exercise interventions. There were subgroup differences for R V˙ O2peak based on exercise modality (p = 0.002) and intervention length (p = 0.01), but there were no differences for A V˙ O2peak. There were subgroup differences (p ≤ 0.018) for PPO based on time since injury, neurological level of injury, exercise modality, and frequency. The meta-regression found that studies with a higher mean age of participants were associated with smaller changes in A V˙ O2peak and R V˙ O2peak (p < 0.10). GRADE indicated a moderate level of certainty in the estimated effect for R V˙ O2peak, but low levels for A V˙ O2peak and PPO. This review may be limited by the small number of RCTs, which prevented a subgroup analysis within this specific study design. Conclusions: Our primary meta-analysis confirms that performing exercise >2 weeks results in significant improvements to A V˙ O2peak, R V˙ O2peak, and PPO in individuals with SCI. The pooled meta-analysis subgroup comparisons identified that exercise interventions lasting up to 12 weeks yield the greatest change in R V˙ O2peak. Upper-body aerobic exercise and resistance training also appear the most effective at improving R V˙ O2peak and PPO. Furthermore, acutely injured, individuals with paraplegia, exercising for ≥3 sessions/week will likely experience the greatest change in PPO. Ageing seemingly diminishes the adaptive CRF responses to exercise training in individuals with SCI. Registration: PROSPERO: CRD42018104342

30 April 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
SBShane J T Balthazaar
Shane J T Balthazaar
DHDaniel D Hodgkiss
Daniel D Hodgkiss
SCShin-Yi Chiou
Shin-Yi Chiou
SLSam Lucas
Sam Lucas
ASAfroditi Stathi
Afroditi Stathi
TNTom E. Nightingale
Tom E. Nightingale
Introduction Individuals with spinal cord injury (SCI) face heightened cardiovascular disease (CVD) risks. While general exercise guidelines are promoted for SCI individuals, when and how to incorporate exercise during the subacute phase post-SCI remains unclear. Consequently, early aerobic exercise to reduce CVD risks is not standard practice in subacute SCI care, potentially missing an opportunity for optimal cardiovascular rehabilitation, especially given observed reductions in cardiac structure and function within the first year post-SCI. Addressing this gap could improve long-term cardiovascular health and health-related quality of life (HRQOL) for individuals with SCI. Early intervention might prevent worsening cardiovascular function and establish beneficial exercise habits. However, few studies have evaluated the effectiveness of early exercise interventions in this population. This study aims to provide insight into the impact of moderate-intensity arm-crank exercise training (ACET) on cardiometabolic, HRQOL, functional and fitness parameters in individuals with subacute (<12 months postinjury) SCI. Methods and analysis We will conduct a single-centre, two-group, single-blind randomised controlled trial with 42 participants who have sustained a cervical or thoracic SCI within the past year. The non-intervention group will receive hospital standard of care (control group) while the intervention group will receive hospital standard of care plus moderate-intensity ACET for 10 weeks in line with the SCI-specific exercise guidelines to improve cardiometabolic health. The primary outcome measure will be central arterial stiffness (carotid-to-femoral pulse wave velocity). Secondary outcomes include assessments of (1) blood biomarkers linked to CVD, (2) cardiac structure and function, (3) extracranial vasculature, (4) HRQOL, (5) cognitive function, (6) physical activity level, (7) cardiorespiratory fitness, (8) motor function and (9) feasibility outcomes. Assessments will occur at baseline (rehabilitation centre admission, −2 weeks), preintervention (0 weeks), postintervention (10 weeks) and follow-up (6 months after postintervention), for HRQOL outcomes only. Ethics and dissemination Ethical approval was obtained from the Wales Research Ethics Committee (HREC 22/WA/0329). Outcome data will be presented at international conferences, patient advocacy groups, health professional networks and community health events. Findings will be published in peer-reviewed journals and widely disseminated through strategic channels to reach researchers, healthcare providers, patients and the public. Trial registration number ISRCTN99941302.

15 January 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
DHDaniel D Hodgkiss
Daniel D Hodgkiss
SBShane J T Balthazaar
Shane J T Balthazaar
JWJoseph F Welch
Joseph F Welch
AWAlex Wadley
Alex Wadley
PCPhoebe A Cox
Phoebe A Cox
TNTom E. Nightingale
Tom E. Nightingale
Introduction Individuals with higher neurological levels of spinal cord injury (SCI) at or above the sixth thoracic segment (≥T6), exhibit impaired resting cardiovascular control and responses during upper-body exercise. Over time, impaired cardiovascular control predisposes individuals to lower cardiorespiratory fitness and thus a greater risk for cardiovascular disease and mortality. Non-invasive transcutaneous spinal cord stimulation (TSCS) has been shown to modulate cardiovascular responses at rest in individuals with SCI, yet its effectiveness to enhance exercise performance acutely, or promote superior physiological adaptations to exercise following an intervention, in an adequately powered cohort is unknown. Therefore, this study aims to explore the efficacy of acute TSCS for restoring autonomic function at rest and during arm-crank exercise to exhaustion (AIM 1) and investigate its longer-term impact on cardiorespiratory fitness and its concomitant benefits on cardiometabolic health and health-related quality of life (HRQoL) outcomes following an 8-week exercise intervention (AIM 2). Methods and analysis Sixteen individuals aged ≥16 years with a chronic, motor-complete SCI between the fifth cervical and sixth thoracic segments will undergo a baseline TSCS mapping session followed by an autonomic nervous system (ANS) stress test battery, with and without cardiovascular-optimised TSCS (CV-TSCS). Participants will then perform acute, single-session arm-crank exercise (ACE) trials to exhaustion with CV-TSCS or sham TSCS (SHAM-TSCS) in a randomised order. Twelve healthy, age- and sex-matched non-injured control participants will be recruited and will undergo the same ANS tests and exercise trials but without TSCS. Thereafter, the SCI cohort will be randomly assigned to an experimental (CV-TSCS+ACE) or control (SHAM-TSCS+ACE) group. All participants will perform 48 min of ACE twice per week (at workloads corresponding to 73–79% peak oxygen uptake), over a period of 8 weeks, either with (CV-TSCS) or without (SHAM-TSCS) cardiovascular-optimised stimulation. The primary outcomes are time to exhaustion (AIM 1) and cardiorespiratory fitness (AIM 2). Secondary outcomes for AIM 1 include arterial blood pressure, respiratory function, cerebral blood velocity, skeletal muscle tissue oxygenation, along with concentrations of catecholamines, brain-derived neurotrophic factor and immune cell dynamics via venous blood sampling pre, post and 90 min post-exercise. Secondary outcomes for AIM 2 include cardiometabolic health biomarkers, cardiac function, arterial stiffness, 24-hour blood pressure lability, energy expenditure, respiratory function, neural drive to respiratory muscles, seated balance and HRQoL (eg, bowel, bladder and sexual function). Outcome measures will be assessed at baseline, pre-intervention, post-intervention and after a 6-week follow-up period (HRQoL questionnaires only). Ethics and dissemination Ethical approval has been obtained from the Wales Research Ethics Committee 7 (23/WA/0284; 03/11/2024). The recruitment process began in February 2024, with the first enrolment in July 2024. Recruitment is expected to be completed by January 2026. The results will be presented at international SCI and sport-medicine conferences and will be submitted for publication in peer-reviewed journals. Trial registration number ISRCTN17856698.

6 November 2025 in Sports Medicine - Open
Verified
Journal Article
Open access
PDF file
DHDaniel D. Hodgkiss
Daniel D. Hodgkiss
SBShane J. T. Balthazaar
Shane J. T. Balthazaar
CGCameron M. Gee
Cameron M. Gee
SCShin-Yi Chiou
Shin-Yi Chiou
SLSamuel J. E. Lucas
Samuel J. E. Lucas
TNTom E. Nightingale
Tom E. Nightingale
Background: Spinal cord injury (SCI) affects motor and autonomic functions that reduce exercise capacity. Specifically, the loss of sympathetic drive following SCI at or above the sixth thoracic segment (≥ T6) can impair cardiovascular responses to exercise. This systematic scoping review aimed to identify ergogenic strategies that may augment the cardiovascular system and acutely enhance exercise performance in individuals with SCI. Methods: A systematic literature search was conducted using electronic databases (Medline, Embase, Web of Science) from inception to 1st April 2025. Studies were included if they met the following eligibility criteria: (1) human participants (aged ≥ 16 years); (2) any acquired SCI (traumatic, infection, cancer); (3) any sample size but must be > 80% SCI; (4) acute, single, volitional exercise sessions with cross-over design (i.e., ergogenic strategy and control sessions); (5) report a measurable exercise performance outcome, and (6) the strategy used to enhance performance must have a theoretical effect on the cardiovascular system. Data were extracted from eligible studies and charted. Hedges’ g summary effect sizes were calculated to quantify the magnitude of effects across strategies. Results: A total of 7266 possible articles were identified. Following a full-text review, 32 articles were included. Findings were reported by strategy, defined as either mechanical (e.g., abdominal binders, lower-body compression, passive leg exercise and supine posture) or neuromodulatory [e.g., autonomic dysreflexia (AD), functional electrical stimulation (FES), pharmaceuticals/supplements/stimulants, and spinal cord stimulation (SCS)]. The neuromodulatory strategies appeared more robust at augmenting cardiovascular and performance outcomes, particularly AD, FES, and SCS. Conclusions: We examined methods to improve acute exercise performance by augmenting the cardiovascular system in individuals with SCI. The large heterogeneity across methodologies and outcome measures made it challenging to draw conclusions regarding the underlying physiological mechanisms. Consequently, providing definitive recommendations on the best strategies to enhance performance was not possible based on current literature. Future research should be conducted across all ergogenic strategies, with a careful focus on females, trained and untrained participants, and individuals who are more likely to benefit from improvements in cardiovascular output (i.e., SCI ≥ T6). Registration This review was pre-registered on the Open Science Framework ( https://osf.io/w7apu/ ).

13 October 2025 in Sports Medicine
Verified
Journal Article
Open access
PDF file
DHDaniel D. Hodgkiss
Daniel D. Hodgkiss
SBShane J. T. Balthazaar
Shane J. T. Balthazaar
CGCameron M. Gee
Cameron M. Gee
IBIan D. Boardley
Ian D. Boardley
TJThomas W. J. Janssen
Thomas W. J. Janssen
TNTom E. Nightingale
Tom E. Nightingale
Electroceuticals such as brain computer interfaces and spinal cord stimulation (SCS) represent transformative strategies for neuromodulation. Research has demonstrated that SCS can ameliorate motor and autonomic cardiovascular dysfunctions, particularly in individuals with spinal cord injury (SCI). Notably, SCS has been shown to augment aerobic exercise performance. Owing to the nature of their injury, athletes with SCI are often predisposed to low resting blood pressure and impaired physiological responses to exercise. Therefore, some athletes intentionally induce autonomic dysreflexia (“boosting”) to gain a competitive advantage – an act banned by the International Paralympic Committee (IPC). However, the emergence of electroceuticals facilitates an alternative performance enhancement strategy that could be considered unfair without equal access opportunities for all athletes. Currently, the World Anti-Doping Agency and the IPC have not acknowledged the potential impact of electroceuticals in parasport. Herein, we present an argument that the use of SCS meets the criteria for it to be placed on the World Anti-Doping Code Prohibited List (or at the very least be monitored) because collectively: SCS can enhance sport performance, represents a potential health risk to the athlete if misused, and may violate the spirit of sport. Acute and chronic use of SCS may also lead to classification changes, and increased opportunities for athletes to intentionally misrepresent, thereby raising concerns for the IPC. The growing access to electroceuticals (e.g. via clinical trial participation or private healthcare implantation) more than ever increases the likelihood of an athlete using SCS to gain an unfair advantage in parasport.